Compare JAZZ & FN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAZZ | FN |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | Ireland | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 14.6B |
| IPO Year | 2007 | 2007 |
| Metric | JAZZ | FN |
|---|---|---|
| Price | $208.12 | $362.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 9 |
| Target Price | $294.64 | ★ $715.56 |
| AVG Volume (30 Days) | 715.2K | ★ 818.7K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.31 |
| EPS | 7.17 | ★ 13.05 |
| Revenue | $1,618,693,000.00 | ★ $4,641,097,000.00 |
| Revenue This Year | $10.65 | $31.54 |
| Revenue Next Year | $5.76 | $19.73 |
| P/E Ratio | $29.35 | ★ $27.99 |
| Revenue Growth | N/A | ★ 35.73 |
| 52 Week Low | $128.80 | $362.64 |
| 52 Week High | $266.38 | $748.89 |
| Indicator | JAZZ | FN |
|---|---|---|
| Relative Strength Index (RSI) | 26.18 | 33.92 |
| Support Level | $194.77 | N/A |
| Resistance Level | $241.39 | $522.28 |
| Average True Range (ATR) | 6.94 | 25.84 |
| MACD | -1.78 | -10.41 |
| Stochastic Oscillator | 4.51 | 0.47 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.